KSQ announced that it has expanded its strategic collaboration with Takeda to research and validate novel tumour-intrinsic targets.
Under the terms of the agreement, Takeda will provide KSQ with an upfront payment and an investment in the double-digit millions of dollars. KSQ is also eligible to receive up to $510 million in future payments if all milestones are achieved during the term of the agreement, plus royalties on potential net sales of any commercial product resulting from the collaboration.
Expanding the successful partnership with Takeda further validates the effectiveness of the CRISPRomics platform in discovering exciting, novel targets in various cell types across modalities. It also demonstrates KSQ
